A phase I study of CD25/regulatory T cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation


Disclosures: Disclosure of Conflict of Interests: The authors have nothing to disclose and cite no competing financial interests. Acknowledgements: The authors would like to thank Miltenyi Biotec for providing CliniMACS reagents and kits for CD25 depletion. This work was supported in part by NIH Grants CA183559, CA183560, and CA142106. SN was supported by Friends of Dana-Farber and the Jock and Bunny Adams Education and Research Endowment. JK was supported as a Scholar in Clinical Research by the Leukemia and Lymphoma Society.

Contributions: SN data analysis, primary manuscript writing; HTK trial design, statistical analysis, manuscript review; HD cellular therapy manufacturing; CR immunophenotyping and data analysis; KTJ data acquisition, trial management; PA trial accrual, manuscript review; VTH trial accrual, manuscript review; EPA trial accrual, manuscript review; CSC trial accrual, manuscript review; JR trial design, cellular therapy manufacturing, data analysis, manuscript review; JHA trial accrual, manuscript review; RJS trial design, trial accrual, manuscript review; JK primary trial design and regulatory oversight, data analysis, manuscript review.